RIVM is among the top 4 of institutes in the area of environment and health research that collaborate most frequently in EU projects, as was demonstrated by a 2017 study for the European Commission. Our experts and researchers are involved in a wide range of international projects. On this page we present an overview of these projects.
|Horizon 2020 projects|
|Third Health Programme projects|
The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA. IMI launches research and/or training projects every year. Project participants are recruited through open and competitive calls for research proposals. The selection of the winning proposals is based on independent peer review. RIVM is a partner in several IMI financed projects.
Innovative Medicines Initiative
Basicly, a Joint Action is a group of coherent activities on a specific topic, which is jointly funded by the European Commission and the EU Member States who have decided to participate in it. Joint Actions have a clear EU added value and are co-financed either by competent authorities that are responsible for health in the Member States or in the third countries participating in the Programme, or by public sector bodies and non-governmental bodies mandated by those competent authorities. As a result, a Joint Action also provides outcomes that offer benefits on the national level.